| BioMimetic Leads the Bulls in Healthcare | | Print | |
| Written by M.E.Garza | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Wednesday, 07 October 2009 00:00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Also among the winners was Elron Electronic Industries Ltd. (NASDAQ:ELRN) which closed up +0.56 (10.89%) to $5.70. This is a multi-faceted play that covers various sectors including healthcare beacuse it's technically a technology operational holding company that operates through its group companies. The company is engaged primarily in the fields of medical devices, information communications, technology, semiconductors and clean technology. Clean tech is being touted by many as the next big opportunity sector for investors. NovaMed, Inc.(NASDAQ:NOVA) closed at $4.58+0.36 (8.53%) and saw nearly half it's gains for the day come in the closing minutes of the regular session. After hour trades were not unusual and didn't show any added volatility or price increase, however. NovaMed, Inc. is a health care services company and an owner and operator of ambulatory surgery centers (ASCs). Leading the losers was MannKind Corporation (NASDAQ:MNKD). Shares of this biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer have plummeted over 31% on Tuesday to $6.31, after the company said it would be unable to conclude a partnership deal for its inhaled insulin product, AFRESA, by the end of the year. DepoMed, Inc.(NASDAQ:DEPO) pulled back just a bit after Monday's big jump for the stock. The company announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA. The primary endpoint measured pain scores from baseline to the end of a ten-week treatment period using the numerical Likert pain scale. Some analysts are reiterating a positive rating for the stock and believe the market has yet to factor in the potential that this drug has in terms of delivering milestones and royalties to the company from partner Abbott Labs. As subscribers to our FDA and Clinical Trials Calendar know, up next for Depomed is the phase III Breeze data testing Serada in menopausal hot flashes. That data is expected to be out later this month and should help continue pushing shares upward. For Wednesday, watch Vical Incorporated (Nasdaq:VICL) the company announced early this morning that the company's TransVax(TM) cytomegalovirus (CMV) vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial. Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, presented the data today at the World Vaccine Congress (Lyon, France). Here are the rest of Tuesday's Top Winners and Losers in healthcare:
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (2)
Vernon Poole
said:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading Tuesday's biggest winners in healthcare was BioMimetic Therapeutics, Inc.(NASDAQ:BMTI). The stock is up over 45% in the last three months.
TrackBack URI for this entry
Subscribe to this comment's feed|
... How does GNBT inhaled insulin product compair to MNKD product? Which is expected to be FDA approved first? |
|
Steven Wagner
said:
|
... Generex Biotechnology (GNBT) has a revolutionary drug delivery device that looks like, but does not act like, an inhaler. It administers large molecule drugs such as insulin through the cheek wall thus avoiding the complications of inhaled drugs. MNKD has a competing method that DOES get inhaled directly into the lungs which may cause problems for smokers and others with lung issues. Since GNBT device does not involve the lungs it does not cause lung cancer. Furthermore, GNBT's drug delivery device has the potential to be a platform device, meaning it can be used to administer a myriad of other drugs previously injected...think of the elderly and very young who have limited ability, good veins, and pain tolerance. MNKD is about 6 months ahead of GNBT but with what I believe is inferior technology and significantly greater risk. GNBT is supposed to release Phase III results either this quarter or next. They already have had excellent Phase II results. IF approved, the potential for this novel drug delivery device is tremendous since there are so many drugs that are injected because they must bypass the gastrointestinal tract. This device does without affecting the lungs. Obviously I am long. |
|
Sign Up For Phone Alerts
